Nomura S, Shinozaki T, Hamada C. Comparison of several approaches to adjust overall survival (OS) for extensive crossovers in placebo-controlled randomized phase 3 trials. At: The 2017 ENAR Spring Meeting, Washington, DC, March 12-15, 2017. Abstract 6h.
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness of first-line S-1 therapy for metastatic breast cancer patients compared with taxanes: an analysis based on the randomized phase III SELECT BC trial. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN161.
Hagiwara Y, Shimozuma K, Shiroiwa T, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impacts of adverse events on health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer : results from randomized phase III SELECT BC study. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN204.
Nozaki T, Kashiwabara K, Shinozaki T, Oba K, Matsuyama Y, Ota E, Mori R. A network meta-analysis of prophylactic antibiotics for preventing post-cesarean endometritis. At: The 24th Cochrane Colloquium, Seoul, Korea. October 23–27, 2016.
Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Fukuda T, Ohashi Y, Mukai H. Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT BC trial. International Society for Quality of Life Research 23rd Annual Conference, Copenhagen, Denmark, October 21. Abstract 2029.
Sho M, Shimizu A, Yanagimoto H, Nakamori S, Okusaka T, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Hagiwara Y, Ohashi Y, Shirasaka T, Yamaue H. Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study. American Society for Clinical Oncology annual meeting 2016, Chicago, US, June, 2016. J Clin Oncol. 2016; 34(suppl; abstr 4107).
Ohki D, Tsuji Y, Shinozaki T, Fujishiro M, Sakaguchi Y, Niimi K, Ono S, Hayakawa Y, Yoshida S, Yamada A, Kodashima S, Yamamichi N, Hirata Y, Koike K. Sessile serrated adenoma detection rate is correlated with adenoma detection rate. At: American Society for Gastrointestinal Endoscopy 2016 Digestive Disease Week, San Diego, CA, May 2016. Abstract is available in: Gastrointestinal Endoscopy, 83(5S), AB192–AB193, Abstract 1007.
Shiraishi K, Shinozaki T. Risk of secondary cancers after breast conserving therapy in Japan. At: 2016 Cancer Survivorship Symposium: Advancing Care and Research, San Francisco, CA, January 2016. Abstract is available in: Journal of Clinical Oncology, 34, 3(January 20 Suppl.), Abstract 256.
Hagiwara Y, Shinozaki T, Matsuyama Y. Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models. UK Causal Inference Meeting 4th annual meeting, London, England, April 13, 2016. P18.
Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, The Liver Cancer Study Group of Japan. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan. 2015 ASCO Annual Meeting, May 29 – June 2, 2015 at the McCormick Place Convention Center in Chicago, Illinois.
Unno M, Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Furukawa T, Ishida K, Takase K, Matsuyama Y, Nakagawa K, Katayose Y. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus surgery-first for resectable pancreatic carcer (Prep-02/JSAP05). 2015 ASCO Annual Meeting, May 29 – June 2, 2015 at the McCormick Place Convention Center in Chicago, Illinois.
Matsumoto Y, Umemura S, Kobayashi N, Tanaka Y, Sasaki C, Shimizu K, Ogawa A, Kinoshita H, Matsuyama Y, Morita T, Goto K, Ohe Y. Early palliative care for patients with metastatic lung cancer receiving chemotherapy: a feasibility study of a nurse-led screening program. 14th World Congress of the European Association for Palliative Care. 5-8 May 2015, Copenhagen, Denmark.
Niikura N, Ohta Y, Hayashi N, Naito M, Kashiwabara K, Watanabe K, Yamashita T, Mukai H, Umeda M. Evaluation of the use of oral care to prevent oral mucositis in estrogen receptor positive metastatic breast cancer patients treated with everolimus: Phase III randomized control trial. At: 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX. December 8–12, 2015. Abstr OT1-03-02.
Fukuda T, Shiroiwa T, Simozuma K, Mori M, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Hagiwara Y, Ohashi Y, Mukai H. Long-term EQ-5D score for patients with metastatic breast cancer; comparison of first-line oral S-1 and Taxane therapies in the randomized SLECT trial. International Society for Pharmacoeconomics and Outcome Research 18th Annual European Congress, Milan, Italy, November 9, 2015. Abstract PCN210.
Nomura S, Shinozaki T, Hamada C. Comparison of several approaches to adjust overall survival (OS) for extensive crossovers in placebo-controlled randomized phase 3 trials. At: 36th Annual Conference of the International Society for Clinical Biostatistics, Utrecht, Netherland. Aug 2015. Abstract C25.01.
Shinozaki T, Matsuyama Y. Doubly robust standardization in cohort studies with a binary exposure and censored events. At: 2015 Joint Statistical Meetings, Seattle, WA. Aug 2015. Abstract 316644.